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Abstract
With the support of ESCMID and European countries, EUCAST has developed a disk diffusion test with zone diameter breakpoints
correlated with the EUCAST clinical MIC breakpoints. The development of the EUCAST disk diffusion method and quality control criteria
are described, together with guidance on quality control and implementation of the method in clinical microbiology laboratories. The
method includes the use of Mueller–Hinton agar without supplements for non-fastidious organisms and with 5% mechanically deﬁbrinated
horse blood and 20 mg/L b-NAD for fastidious organisms, a standardized inoculum resulting in conﬂuent growth, an incubation time of 16–
20 h, a reading guide on how to read zone diameters on individual species-agent combinations and zone diameter breakpoints calibrated to
the EUCAST clinical MIC breakpoints. EUCAST recommendations are described in detail and updated regularly on the EUCAST website
(http://www.eucast.org).
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Abstract
The increasing prevalence of hospital and community-acquired infections caused by multidrug-resistant (MDR) bacterial pathogens is rapidly
limiting the options for effective antibiotic therapy. Systematic studies on combinations of already available antibiotics that could provide an
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effective treatment against MDR bacteria are needed. We tested combinations of antibiotics that target one important physiological
function (peptidoglycan synthesis) at several steps, and studied Enterobacteriaceae (Klebsiella pneumoniae and Escherichia coli) for which
multidrug resistance associated with ESBL-producing plasmids has become a major problem. To measure the effectiveness of antibiotics
alone and in combination, we used checkerboard assays, static antibiotic concentration time-kill assays, and an improved in-vitro kinetic
model that simulates human pharmacokinetics of multiple simultaneously administered antibiotics. The target strains included an MDR
K. pneumoniae isolate responsible for a recent major hospital outbreak. A double combination (fosfomycin and aztreonam) and a triple
combination (fosfomycin, aztreonam and mecillinam) were both highly effective in reducing bacterial populations in all assays, including the in
vitro kinetic model. These combinations were effective even though each of the MDR strains was resistant to aztreonam alone. Our results
provide an initial validation of the potential usefulness of a combination of antibiotics targeting peptidoglycan synthesis in the treatment of
MDR Gram-negative bacteria. We suggest that a combination of fosfomycin with aztreonam could become a useful treatment option for
such infections and should be further studied.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 368–369
CMI Online-nly Abstracts 369
